Publications
Detailed Information
Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, J. | - |
dc.contributor.author | Lee, C.-H. | - |
dc.contributor.author | Kim, D.K. | - |
dc.contributor.author | Yoon, H.I. | - |
dc.contributor.author | Kim, J.Y. | - |
dc.contributor.author | Lee, S.-M. | - |
dc.contributor.author | Yang, S.-C. | - |
dc.contributor.author | Lee, J. | - |
dc.contributor.author | Yoo, C.-G. | - |
dc.contributor.author | Lee, C.-T. | - |
dc.contributor.author | Chung, H.S. | - |
dc.contributor.author | Kim, Y.W. | - |
dc.contributor.author | Han, S.K. | - |
dc.contributor.author | Yim, J.-J. | - |
dc.date.accessioned | 2024-08-08T01:46:42Z | - |
dc.date.available | 2024-08-08T01:46:42Z | - |
dc.date.created | 2022-10-06 | - |
dc.date.created | 2022-10-06 | - |
dc.date.issued | 2011 | - |
dc.identifier.citation | The Korean Journal of Internal Medicine, Vol.26 No.2, pp.153-159 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://hdl.handle.net/10371/208055 | - |
dc.description.abstract | Background/Aims: To compare the effect of levofloxacin and moxifloxacin on treatment outcomes among patients with multidrug-resistant tuberculosis (MDR-TB). Methods: A retrospective analysis of 171 patients with MDR-TB receiving either levofloxacin or moxifloxacin was performed. Treatment responses were categorized into treatment success (cured and treatment completed) or adverse treatment outcome (death, failure, and relapsed). Results: The median age of the patients was 42.0 years. Approximately 56% of the patients were male. Seventeen patients had extensively drug-resistant tuberculosis, and 20 had a surgical resection. A total of 123 patients (71.9%) received levofloxacin for a median 594 days, and 48 patients (28.1%) received moxifloxacin for a median 673 days. Other baseline demographic, clinical, and radiographic characteristics were similar between the two groups. The moxifloxacin group had a significantly higher number of resistant drugs (p < 0.001) and a higher incidence of resistance to ofloxacin (p = 0.005) in the drug sensitivity test. The treatment success rate was 78.9% in the levofloxacin group and 83.3% in the moxifloxacin group (p = 0.42). Adverse reactions occurred at similar rates in the groups (p = 0.44). Patients in the moxifloxacin group were not more likely to have treatment success than those in the levofloxacin group (adjusted odds ratio, 0.76; 95% confidence interval, 0.24 to 2.43; p = 0.65). Conclusions: Both levofloxacin and moxifloxacin showed equivalent efficacy for treating MDR-TB. © 2011 The Korean Association of Internal Medicine. | - |
dc.language | 영어 | - |
dc.publisher | 대한내과학회 | - |
dc.title | Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes | - |
dc.type | Article | - |
dc.identifier.doi | 10.3904/kjim.2011.26.2.153 | - |
dc.citation.journaltitle | The Korean Journal of Internal Medicine | - |
dc.identifier.scopusid | 2-s2.0-79959818137 | - |
dc.citation.endpage | 159 | - |
dc.citation.number | 2 | - |
dc.citation.startpage | 153 | - |
dc.citation.volume | 26 | - |
dc.identifier.kciid | ART001556830 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Lee, S.-M. | - |
dc.contributor.affiliatedAuthor | Lee, C.-T. | - |
dc.contributor.affiliatedAuthor | Chung, H.S. | - |
dc.contributor.affiliatedAuthor | Kim, Y.W. | - |
dc.contributor.affiliatedAuthor | Yim, J.-J. | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordAuthor | Levofloxacin | - |
dc.subject.keywordAuthor | Moxifloxacin | - |
dc.subject.keywordAuthor | Multidrug-resistant | - |
dc.subject.keywordAuthor | Quinolones | - |
dc.subject.keywordAuthor | Tuberculosis | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.